Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher diseaseParis, May 28, 2026. The US Food and Drug ...
18m
Sanofi: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The US Food and Drug Administration (FDA) has granted priority review to the new drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results